XLO (STOCKS)
Xilio Therapeutics, Inc. Common Stock
$0.535000
-0.006500 (-1.20%)
Prev close: $0.541500
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- René Russo
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $36.25M
- Employees
- 73
- P/E (TTM)
- -0.82
- P/B (TTM)
- -3.47
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
2
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.01 | $-0.03 | +0.0243 | +80.20% |
|
Jun 2025 (Q2)
|
$-0.16 | $-0.08 | -0.0792 | -98.02% |
|
Mar 2025 (Q1)
|
$-0.18 | $0.10 | -0.2760 | -287.50% |
|
Dec 2024 (Q4)
|
$-0.20 | $-0.22 | +0.0188 | +8.59% |
Financial Statements
| Revenues | $31.80M |
| Benefits Costs and Expenses | $90.29M |
| Costs And Expenses | $90.29M |
| Nonoperating Income/Loss | -$14.71M |
| Operating Expenses | $75.58M |
| Research and Development | $46.75M |
| Other Operating Expenses | $28.83M |
| Operating Income/Loss | -$43.78M |
| Income/Loss From Continuing Operations After Tax | -$58.49M |
| Income/Loss From Continuing Operations Before Tax | -$58.49M |
| Net Income/Loss | -$58.49M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$58.49M |
| Net Income/Loss Available To Common Stockholders, Basic | -$58.49M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.61 |
| Diluted Earnings Per Share | -$0.61 |
| Basic Average Shares | 109,087,829 |
| Assets | $133.69M |
| Current Assets | $124.09M |
| Noncurrent Assets | $9.61M |
| Fixed Assets | $3.68M |
| Other Non-current Assets | $5.93M |
| Liabilities | $141.79M |
| Current Liabilities | $56.40M |
| Accounts Payable | $2.30M |
| Other Current Liabilities | $54.10M |
| Noncurrent Liabilities | $85.39M |
| Equity | -$8.10M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$8.10M |
| Liabilities And Equity | $133.69M |
| Net Cash Flow From Operating Activities | -$17.15M |
| Net Cash Flow From Operating Activities, Continuing | -$17.15M |
| Net Cash Flow From Investing Activities | -$429.00K |
| Net Cash Flow From Investing Activities, Continuing | -$429.00K |
| Net Cash Flow From Financing Activities | $60.11M |
| Net Cash Flow From Financing Activities, Continuing | $60.11M |
| Net Cash Flow | $42.53M |
| Net Cash Flow, Continuing | $42.53M |
| Comprehensive Income/Loss | -$58.49M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$58.49M |
| Other Comprehensive Income/Loss | $0.00 |